These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 22569083)
1. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Beales IL; Vardi I; Dearman L Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):917-23. PubMed ID: 22569083 [TBL] [Abstract][Full Text] [Related]
2. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ; Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200 [TBL] [Abstract][Full Text] [Related]
3. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study. Beales IL; Vardi I; Dearman L; Broughton T Dis Esophagus; 2013; 26(8):838-46. PubMed ID: 22989236 [TBL] [Abstract][Full Text] [Related]
4. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286 [TBL] [Abstract][Full Text] [Related]
5. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Tan MC; El-Serag HB; Yu X; Thrift AP Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826 [TBL] [Abstract][Full Text] [Related]
6. Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis. Beales IL; Dearman L; Vardi I; Loke Y Dig Dis Sci; 2016 Jan; 61(1):238-46. PubMed ID: 26386857 [TBL] [Abstract][Full Text] [Related]
7. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Tsibouris P; Hendrickse MT; Isaacs PE Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913 [TBL] [Abstract][Full Text] [Related]
8. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study. Nguyen T; Duan Z; Naik AD; Kramer JR; El-Serag HB Gastroenterology; 2015 Nov; 149(6):1392-8. PubMed ID: 26208896 [TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456 [TBL] [Abstract][Full Text] [Related]
10. Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma. Thomas T; Loke Y; Beales ILP J Gastrointest Cancer; 2018 Dec; 49(4):442-454. PubMed ID: 28691139 [TBL] [Abstract][Full Text] [Related]
11. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. Choi SE; Perzan KE; Tramontano AC; Kong CY; Hur C Cancer Prev Res (Phila); 2014 Mar; 7(3):341-50. PubMed ID: 24380852 [TBL] [Abstract][Full Text] [Related]
13. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Nguyen DM; Richardson P; El-Serag HB Gastroenterology; 2010 Jun; 138(7):2260-6. PubMed ID: 20188100 [TBL] [Abstract][Full Text] [Related]
14. Statin use and risk of colorectal cancer. Coogan PF; Smith J; Rosenberg L J Natl Cancer Inst; 2007 Jan; 99(1):32-40. PubMed ID: 17202111 [TBL] [Abstract][Full Text] [Related]
15. Statin use is associated with a decreased risk of Barrett's esophagus. Nguyen T; Khalaf N; Ramsey D; El-Serag HB Gastroenterology; 2014 Aug; 147(2):314-23. PubMed ID: 24798416 [TBL] [Abstract][Full Text] [Related]
16. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. Gatenby PA; Ramus JR; Caygill CP; Winslet MC; Watson A Eur J Cancer Prev; 2009 Sep; 18(5):381-4. PubMed ID: 19620873 [TBL] [Abstract][Full Text] [Related]
17. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. Jankowski JA; Anderson M Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468 [TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. Wang F; Lv ZS; Fu YK Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737 [TBL] [Abstract][Full Text] [Related]
19. Chemoprevention in Barrett's oesophagus. Gordon V; Jankowski J Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):569-79. PubMed ID: 22122772 [TBL] [Abstract][Full Text] [Related]
20. Chemoprevention in Barrett's oesophagus. Baruah A; Buttar NS Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):151-65. PubMed ID: 25743463 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]